Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Multivalent Recombinant OspA Vaccine Candidate Against Lyme Borreliosis, In Healthy Adults Aged Below 40 Years
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 10 Nov 2017
At a glance
- Drugs VLA 15 (Primary)
- Indications Lyme disease
- Focus Adverse reactions
- Sponsors Valneva
- 24 Jul 2017 According to a Valneva media release, the company expects to announce first results from the study in the first quarter of 2018.
- 12 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 21 Mar 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Sep 2017.